Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.00
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 564 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Greenwich LifeSciences, Inc.
Market Cap
$246.59M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$243.84M
Debt to Equity Ratio
9.64
TTM Avg
54.87
3Y Avg
37.52
5Y Avg
22.91
Market Cap
$242.85M
Debt to Equity Ratio
N/A
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
1.23
Market Cap
$239.63M
Debt to Equity Ratio
2.16
TTM Avg
6.63
3Y Avg
12.85
5Y Avg
7.19
Market Cap
$245.60M
Debt to Equity Ratio
0.21
TTM Avg
0.17
3Y Avg
0.14
5Y Avg
0.13
Market Cap
$240.38M
Debt to Equity Ratio
N/A
TTM Avg
5.55
3Y Avg
2.78
5Y Avg
1.85
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $246.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| Invivyd, Inc. (IVVD)vs › | $246.44M | 0.05 | 0.01 | 0.01 | 0.01 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.84M | 9.64 | 54.87 | 37.52 | 22.91 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.85M | N/A | 0.09 | 0.09 | 1.23 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.63M | 2.16 | 6.63 | 12.85 | 7.19 |
| InflaRx N.V. (IFRX)vs › | $240.09M | 0.01 | 0.01 | 0.01 | 0.01 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $245.60M | 0.21 | 0.17 | 0.14 | 0.13 |
| Galectin Therapeutics Inc. (GALT)vs › | $240.38M | N/A | 5.55 | 2.78 | 1.85 |
| High Tide Inc. (HITI)vs › | $237.69M | 1.17 | 1.11 | 0.80 | 1.37 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $256.77M | 0.03 | 0.06 | 0.07 | 0.04 |
Debt/Equity
0.00
Current Ratio
1.54
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.01 |
| 2020-09-30 | 0.14 |
| 2020-06-30 | -0.44 |
| 2020-03-31 | -0.45 |
| 2019-12-31 | -0.47 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.00 |
